Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy

Chemotherapy is designed to induce cell death. However, at non-lethal doses, cancer cells can choose to remain proliferative or become senescent. The slow development of senescence makes studying this decision challenging. Here, by analyzing single-cell p21 dynamics before, during, and days after drug treatment, we link three distinct patterns of early p21 dynamics to final cell fate. Surprisingly, while high p21 expression is classically associated with senescence, we find the opposite at early times during drug treatment: most senescence-fated cells express much lower p21 levels than proliferation-fated cells. We demonstrate that these dynamics lead to a p21 “Goldilocks zone” for proliferation, in which modest increases of p21 expression can lead to an undesirable increase of cancer cell proliferation. Our study identifies a counter-intuitive role for early p21 dynamics in the cell-fate decision and pinpoints a source of proliferative cancer cells that can emerge after exposure to non-lethal doses of chemotherapy. [Display omitted] •Single-cell tracking unravels heterogeneity in drug-induced senescence decisions•Different cell fates are reached through three distinct patterns of p21 dynamics•Most senescence-fated cells have high DNA damage but express low p21 at early times•A p21 “Goldilocks zone” promotes a proliferation cell fate after treatment The proliferation-senescence cell-fate decision after drug treatment is determined by three distinct patterns of p21 dynamics. Either a delayed or acute drug-induced p21 response leads to a senescence fate, while an intermediate pulse of p21 response leads to a proliferation fate. This relation between p21 dynamics and cell fate creates a p21 “Goldilocks zone” that favors cell proliferation after drug treatment.